Collagen vascular diseases of the lung

Clinical Pulmonary Medicine

Volumn 13, Issue 1, 2006, Pages 25-36

  Frankel, Stephen K ^b   Brown, Kevin K ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

Autoimmune disease; ILD; Rheumatoid arthritis; Scleroderma

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLERGIC PNEUMONITIS; AUTOIMMUNE DISEASE; BRONCHIOLITIS OBLITERANS; COLLAGEN DISEASE; DERMATOMYOSITIS; HUMAN; INFECTIOUS COMPLICATION; INFLAMMATION; INTERSTITIAL LUNG DISEASE; KIDNEY; LUNG; LUNG BLOOD VESSEL; LUNG COMPLICATION; LUNG DISEASE; LUNG FIBROSIS; LUPUS LIKE SYNDROME; MIXED CONNECTIVE TISSUE DISEASE; PLEURA DISEASE; PNEUMONIA; POLYMYOSITIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE;

EID: 31044456818     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000197403.64631.de     Document Type: Review

References (120)

1. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc. 1999;74:275-284.
2. Frankel SK. Drug-induced lung disease. In: Hanley M, Welsh C, eds. Current Diagnosis and Treatment in Pulmonary Medicine, New York: Lange/McGraw Hill; 2003:337-347.
3. Zitnik RJ, Cooper JAJ. Pulmonary disease due to antirheumatic agents. Clin Chest Med. 1990;11:139-150.
4. Chakravarty K, Webley M. A longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine. Br J Rheumatol. 1992;31:829-833.
5. Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994;21:51-54.
6. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356-364.
7. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40:1829-1837.
8. Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186-195.
9. Louie S, Gamble CN, Cross CE. Penicillamine associated pulmonary hemorrhage. J Rheumatol. 1986;13:963-966.
10. Evans RB, Ettensohn DB, Fawaz-Estrup F, et al. Gold lung: recent developments in pathogenesis, diagnosis, and therapy. Semin Arthritis Rheum. 1987;16:196-205.
11. Tomioka R, King TEJ. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med. 1997;155:1011-1020.
12. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21:33-36.
13. Godeau B, Coutant-Perronne V, Huong DLT, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246-251.
14. Hellman DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine. 1987;66:341-348.
15. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345-351.
16. Abu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22:1259-1264.
17. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patients with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:10-17.
18. Frankel SK, Sullivan EJ, Brown KK. Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa and Takayasu arteritis. Crit Care Clin. 2002;18:855-879.
19. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528-535.
20. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum. 1987;16:174-185.
21. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography and pulmonary function tests. Thorax. 2001;56:622-627.
22. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 1998;19:667-685, viii.
23. Cervantes-Perez P, Toro-Perez AH, Rodiguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. JAMA. 1980;243:1715-1719.
24. Lamblin C, Bergoin C, Saelens T, et al. Interstitial lung diseases in collagen vascular diseases. Eur Respir J. 2001;18:69S-80S.
25. Anaya JM, Diethelm L, Ortiz L, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:242-254.
26. Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47:508-512.
27. Cheema GS, Quismorio FP. Interstitial lung disease in systemic sclerosis. Curr Opin Pulm Med. 2001;7:283-290.
28. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176:755-759.
29. Cortet B, Flipo RM, Remy-Jardin M, et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:815-819.
30. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology. 1994;193:375-382.
31. Freemer MM, King TEJ. Connective tissue diseases. In: Schwarz MI, King TEJ, eds. Interstitial Lung Disease. Hamilton: BC Decker; 2003:535-598.
32. Schwarz MI, Zamora MR, Hodges TN, et al. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest. 1998;113:1609-1615.
33. Vassallo R, Matteson E, Thomas CFJ. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition. Chest. 2002;122:1093-1095.
34. Vergnenegre A, Pugnere N, Antonini MT, et al. Airway obstruction and rheumatoid arthritis. Eur Respir J. 1997;10:1072-1078.
35. Geddes DM, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis. 1979;38:222-225.
36. Radoux V, Menard HA, Begin R, et al. Airways disease in rheumatoid arthritis patients. Arthritis Rheum. 1987;30:249-256.
37. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional and HRCT findings. Am J Respir Crit Care Med. 1998;157:1658-1665.
38. Shadick NA, Fanta CH, Weinblatt ME, et al. Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine. 1994;73:161-170.
39. Hayakawa H, Sato A, Imokawa S, et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med. 1996;154:1531-1536.
40. Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis. Eur Respir J. 1994;7:817-820.
41. Homma S, Kawabata M, Kishi K, et al. Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J. 1998;12:444-452.
42. Helmers R, Galvin J, Hunninghake GW. Pulmonary manifestations associated with rheumatoid arthritis. Chest. 1991;100:235-239.
43. Caplan A. Certain unusual radiographic appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax. 1953;8:19-37.
44. Joseph J, Sahn SA. Connective tissue diseases and the pleura. Chest. 1993;104:262-270.
45. Sahn SA. State of the art. The pleura. Am Rev Respir Dis. 1988;138:184-234.
46. Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine. 1968;47:501-519.
47. Morikawa J, Kitamura K, Habuchi Y, et al. Pulmonary hypertension in a patient with rheumatoid arthritis. Chest. 1988;93:876-878.
48. Ohosone Y, Okano Y, Kameda H, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299-2303.
49. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine. 1993;72:113-124.
50. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 1998;19:641-665, viii.
51. Pisetsky DS, Gilkeson G, St. Clair EW. Systemic lupus erythematosus. Med Clin North Am. 1997;81:113-127.
52. Halla JT, Schrohenloher RE, Volanakis JE. Immune complexes and other laboratory features of pleural effusions. Ann Intern Med. 1980;92:748-752.
53. Khare V, Baethge BA, Lang S, et al. Antinuclear antibodies in pleural fluid. Chest. 1994;106.
54. Good JRJ, King TEJ, Antony VB, et al. Lupus pleuritis: Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest. 1983;84:714-718.
55. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Am J Med. 1981;71:791-798.
56. Cheema GS, Quismorio FP. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med. 2000;6:424-429.
57. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine. 1975;54:397-404.
58. Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Medicine. 1997;76:192-202.
59. Warrington KJ, Moder KG, Brutinel WM. The shrinking lung syndrome in systemic lupus erythematosus. Mayo Clin Proc. 2000;75:467-472.
60. Karim MY, Miranda LC, Tench CM, et al. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum. 2002;31:289-298.
61. Ishii M, Uda H, Yamagami T, et al. Possible association of 'shrinking lung' and anti-Ro/SSA antibody. Arthritis Rheum. 2000;43:2612-2613.
62. Martens J, Demedts MT, Vanmeenen MS, et al. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest. 1983;84:170-175.
63. Asherson RA, Higgenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol. 1990;17:1292-1298.
64. Simonson JS, Schiller NB, Petri M, et al. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol. 1989;16:918-925.
65. Cervera R, Piette J-C, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027.
66. Abramson SB, Dobro J, Eberle MA, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med. 1991;114:942-947.
67. Martin L, Edworthy SM, Ryan JP, et al. Upper airway disease in systemic lupus erythematosus: a report of 4 cases and a review of the literature. J Rheumatol. 1992;19:1186-1190.
68. Kinney WW, Angelillo VA. Bronchiolitis in systemic lupus erythematosus. Chest. 1982;82:646-649.
69. Altman RD, Medsger TA, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34:403-413.
70. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
71. Mitchell H, Bolster MB, LeRoy EC. Scleroderma and related conditions. Med Clin North Am. 1997;81:129-149.
72. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31:196-203.
73. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med. 1998;19:713-731, viii-ix.
74. Arroliga AC, Podell DN, Matthay RA. Pulmonary manifestations of scleroderma. J Thorac Imaging. 1992;7:30-45.
75. Schlesinger C, Veeraraghavan S, Koss MN. Constructive (obliterative) bronchiolitis. Curr Opin Pulm Med. 1998;4:288-293.
76. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-1586.
77. Steen VD. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62:97-99.
78. Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 1985;28:759-767.
79. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-1289.
80. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001;28:2454-2459.
81. Cox D, Conant E, Earle L, et al. Sarcoidosis in systemic sclerosis: report of 7 cases. J Rheumatol. 1995;22:881-885.
82. Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 1999;58:635-40.
83. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88:470-476.
84. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132:947-954.
85. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993;20:838-844.
86. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994;37:729-735.
87. Steen VD, Lanz JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1290-1296.
88. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986;29:515-524.
89. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996;110:1515-1519.
90. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34.
91. Plotz PH, Dalakas M, Leff RL, et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders. Ann Intern Med. 1989;111:143-157.
92. Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis. 1985;28:249-255.
93. Schwarz MI. The lung in polymyositis. Clin Chest Med. 1998;19:701-712, viii.
94. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.
95. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-407.
96. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985;12:1140-1148.
97. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum. 1984;14:60-76.
98. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182-1185.
99. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614-622.
100. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis. Chest. 2003;123:1096-1103.
101. Herbert CA, Byrnes TJ, Baethge BA, et al. Exercise limitation in patients with polymyositis. Chest. 1990;98:352-357.
102. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren's syndrome. Clin Chest Med. 1998;19:687-699.
103. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren's syndrome. Chest. 1985;88:226-229.
104. Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58:61-64.
105. Lahdensuo A, Korpela M. Pulmonary findings in patients with primary Sjögren's syndrome. Chest. 1995;108:316-319.
106. Cosgrove GP, Fessler MB, Schwarz MI. Lymphoplasmacytic infiltration of the lung. In: Schwarz MI, King TEJ, eds. Interstitial Lung Disease. Hamilton: BC Decker; 2003:825-837.
107. Uffmann M, Kiener HP, Bankier AA, et al. Lung manifestations in asymptomatic patients with primary Sjögren's syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging. 2001;16:282-289.
108. Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Am J Respir Crit Care Med. 1996;154:794-799.
109. Yamadori I, Fujita J, Bandoh S, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren's syndrome. Rheumatol Int. 2002;22:89-92.
110. Lois M, Roman J, Holland W, et al. Coexisting Sjögren's syndrome and sarcoidosis in the lung. Semin Arthritis Rheum. 1998;28:31-40.
111. Gardiner P, Ward C, Allison A, et al. Pleuropulmonary abnormalities in primary Sjögren's syndrome. J Rheumatol. 1993;20:831-837.
112. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sj''gren's syndrome. Clin Chest Med. 1998;19:687-699, viii.
113. Hassen LA, Prakash UB, Colby TV. Pulmonary lymphoma in Sjögren's syndrome. Mayo Clin Proc. 1989;64:920-931.
114. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-892.
115. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52:148-159.
116. Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med. 1998;19:733-746, ix.
117. Nimelstein SH, Brody S, McShane D, et al. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine. 1980;59:239-248.
118. Derderian SS, Tellis CJ, Abbrecht PH, et al. Pulmonary involvement in mixed connective tissue disease. Chest. 1985;88:45-48.
119. Hosoda Y, Suzuki Y, Takano M, et al. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol. 1987;14:826-830.
120. Prakash UB, Luthra HS, Divertie MB. Intrathoracic manifestations ill mixed connective tissue disease. Mayo Clin Proc. 1985;60:813-821.